BBVA USA’s Pfizer PFE Stock Holding History

BBVA USA’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$9.24M	Sell	214,799 -5,059	-2%	-$224K	0.54%	37
2021 Q2	$8.61M	Buy	+219,858	New	+$8.55M	0.48%	45

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

BBVA USA's PFE Position: Q3 2021 in Review

BBVA USA reduced its Pfizer (PFE) stake by 2.3% in Q3 2021, selling an estimated $224K and leaving 214,799 shares worth $9.24M. The position accounts for 0.54% of the portfolio, ranked #37.

BBVA USA first reported a position in PFE in Q2 2021 and has held it in 2 quarters since. 2,803 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

BBVA USA held 214,799 shares of Pfizer worth $9.24M as of Q3 2021.
BBVA USA sold 5,059 Pfizer shares in Q3 2021, an estimated $224K.
Pfizer made up 0.54% of BBVA USA's portfolio in Q3 2021, its #37 holding.
BBVA USA first reported a position in Pfizer in Q2 2021 and has held it in 2 quarters since.
2,803 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.